Jefferies sees Arbutus (ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK ...

2024年10月8日，杜克大学Nicholas S Heaton携手mRNA诺奖得主Drew Weissman在《Nature Communications》杂志上发表题为“Improved influenza vaccine responses ...

mRNA vaccines offer clear advantages and disadvantages ... “In addition, advances in delivery technologies over current gold-standard LNP approaches to improve immunogenicity and reduce dosing ...

COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).

The vaccine – developed by researchers at the University of Florida (UF) in the US – is based on mRNA taken from the patient’s tumour that is delivered in a lipid nanoparticle (LNP ...

MRNA-1273.213 is under clinical development by Moderna and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Mandy Cohen, director of the U.S. Centers for Disease Control and Prevention (CDC), pointed to mRNA as a preferred platform for the shot since vaccines can be developed and distributed quickly.

Novel peptide-modified lipid nanoparticles can cross the blood–brain barrier and target neurons, taking one step closer to ...

Since 1794, LNP — and those newspapers that preceded it — have been central to Lancaster County life. Tracing its roots to the start of the Lancaster Journal in 1794, LNP celebrated 225 years ...

MRNA) to "hold" from "buy," on declining sales of its COVID-19 vaccine and limited near-term growth prospects. We recently compiled a list of the 10 Stocks That Will Bounce Back According To Hedge ...

Five years after the virus that causes COVID emerged in China it still holds some mysteries. The disease has killed an ...